116th Congress Senate S.102 – Prescription Drug Price Relief Act of 2019 S.366 – FLAT Prices Act S.378 – Stop Price Gouging Act S.474 – Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 S.476 – Creating… Continue Reading
Selected cases where infringement exists, but a federal judge permits ongoing infringement. 2006. June 14: z4 Techs., Inc. v. Microsoft Corp., 434 F. Supp. 2d 437, 439 (E.D. Tex. 2006) Patents 6,044,471 and 6,785,825 disclose methods for limiting the unauthorized… Continue Reading
Open letter on NIST Draft Green Paper on Bayh-Dole Act Policies and Regulations 5 April 2019 FMI: Claire Cassedy, claire.cassedy@keionlineorg +1.202.332.2670 Washington, 5 April 2019 – Eleven non-governmental organizations have sent a letter to members of the US Congress, highlighting… Continue Reading
Ventana Medical Systems, Inc., march-in request 1999. February 10. Jonathan Cohen, Director of Intellectual Property for Ventana Medical Systems, Inc., sends letter to Paul A. Gottlieb, Esq., Assistant General Counsel for Technology Transfer and Intellectual Property at the U.S. Department… Continue Reading
This timeline provides copies of official documents not published before about the U.S. pressures in the Dominican Republic during the congressional debates that led to the adoption of the TRIPS-implementing legislation Law 20-00. These documents were obtained via FOIA requests.… Continue Reading
For a general timeline of the Bayh-Dole Act, see this page. 1999. September 3. Ralph Nader, James Love, and Robert Weissman requests the NIH Director Harold Varmus, M.D., to use royalty-free rights and give the WHO access to several U.S. government… Continue Reading
For a general timeline of the Bayh-Dole Act, see this page. 1980. December 12. The Bayh-Dole Act was enacted into law as part of Public Law 96-517, including Section 203 that provide march-in rights. 1984. November 8. The Bayh-Dole statute was… Continue Reading
HOUSE REPORT NO. 96-1307 (Part II), SEPT. 23, 1980 Additional views of Honorable Jack Brooks The major problem I have with H.R. 6933 is that it violates a basic provision of the unwritten contract between the citizens of this country… Continue Reading
On March 6, 2019, 83 civil society organizations and 20 individuals asked delegates to the World Health Assembly (WHA) to support a proposed resolution on “Improving the transparency of markets for drugs, vaccines and other health-related technologies.” A copy of… Continue Reading
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading